364 related articles for article (PubMed ID: 24963213)
1. Biomarkers of inflammatory bowel disease.
Fengming Y; Jianbing W
Dis Markers; 2014; 2014():710915. PubMed ID: 24963213
[TBL] [Abstract][Full Text] [Related]
2. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
[TBL] [Abstract][Full Text] [Related]
3. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
4. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
[TBL] [Abstract][Full Text] [Related]
5. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.
Jiang W; Li X
Mol Diagn Ther; 2015 Jun; 19(3):141-58. PubMed ID: 25990388
[TBL] [Abstract][Full Text] [Related]
6. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG; Gomollon F
Inflamm Bowel Dis; 2009 Nov; 15(11):1746-54. PubMed ID: 19363798
[TBL] [Abstract][Full Text] [Related]
7. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.
Soubières AA; Poullis A
Inflamm Bowel Dis; 2016 Aug; 22(8):2016-22. PubMed ID: 27416044
[TBL] [Abstract][Full Text] [Related]
8. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
[TBL] [Abstract][Full Text] [Related]
9. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Inflammation in Inflammatory Bowel Disease.
Sands BE
Gastroenterology; 2015 Oct; 149(5):1275-1285.e2. PubMed ID: 26166315
[TBL] [Abstract][Full Text] [Related]
11. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
Julsgaard M; Hvas CL; Gearry RB; Vestergaard T; Fallingborg J; Svenningsen L; Kjeldsen J; Sparrow MP; Wildt S; Kelsen J; Bell SJ
Inflamm Bowel Dis; 2017 Jul; 23(7):1240-1246. PubMed ID: 28498159
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):171-7. PubMed ID: 11321388
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.
Ashorn S; Honkanen T; Kolho KL; Ashorn M; Välineva T; Wei B; Braun J; Rantala I; Luukkaala T; Iltanen S
Inflamm Bowel Dis; 2009 Feb; 15(2):199-205. PubMed ID: 18618670
[TBL] [Abstract][Full Text] [Related]
16. Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
Smith LA; Gaya DR
World J Gastroenterol; 2012 Dec; 18(46):6782-9. PubMed ID: 23239916
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in inflammatory bowel disease: current practices and recent advances.
Iskandar HN; Ciorba MA
Transl Res; 2012 Apr; 159(4):313-25. PubMed ID: 22424434
[TBL] [Abstract][Full Text] [Related]
18. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease.
Canani RB; de Horatio LT; Terrin G; Romano MT; Miele E; Staiano A; Rapacciuolo L; Polito G; Bisesti V; Manguso F; Vallone G; Sodano A; Troncone R
J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):9-15. PubMed ID: 16385247
[TBL] [Abstract][Full Text] [Related]
19. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
[TBL] [Abstract][Full Text] [Related]
20. Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases.
Matowicka-Karna J
Postepy Hig Med Dosw (Online); 2016 Apr; 70():305-12. PubMed ID: 27117106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
